A Phase 3 interventional study of Anastozole (Arimidex) and Tamoxifen (Nolvadex) in Breast Cancer, sponsored by AstraZeneca. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing anastrozole in Breast Neoplasms — 17 open to participants now, 28 under way, 10 of them phase 3. Anastrozole · Breast Neoplasms.
Among the 111 studies testing anastrozole in Breast Neoplasms, this one has the largest enrollment of the 109 interventional ones that give a count, is one of 4 that started in 1996, is one of 38 in phase 3, and was the 41st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →17 of the 111 studies testing anastrozole in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 50+ · Women only
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–75 · Women only
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–99
By country, each count listing its studies:
Anastrozole: first FDA approval 1995 (ARIMIDEX). What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 45 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, anastrozole is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 57 · Phase 3 38 · Phase 4 7
First in 1996; this study’s year is marked. 4 started in 1996.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9,358 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 148 across the 109 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 111 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one has the largest enrollment of the 125 interventional ones that give a count, is one of 4 that started in 1996, is one of 46 in phase 3, and was the 71st registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
4 of the studies testing anastrozole in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT03304080Icahn School of Medicine at Mount SinaiAnastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 111 studies testing anastrozole in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arimidex 1mg + Nolvadex placebo
Drug: Anastozole (Arimidex) · Drug: Tamoxifen (Nolvadex) placebo
Arimidex placebo + Nolvadex 20mg
Drug: Tamoxifen (Nolvadex) · Drug: Anastozole (Arimidex) placebo
Arimidex 1mg + Nolvadex 20mg
Drug: Anastozole (Arimidex) · Drug: Tamoxifen (Nolvadex)
1mg, orally, once daily
Also known as: Arimidex
20mg, orally, once daily
Also known as: Nolvadex
1mg, orally, once daily
20mg, orally, once daily
Time to recurrence of breast cancer
Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death
Safety and side effects
Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death
Time to distant recurrence
Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death
Survival
Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death
New breast primaries
Time frame: Earliest of local or distant recurrence, new primary breast cancer, or death
No study locations are listed for this record.
The record gives a start of Jul 1996, a primary completion of Jun 2001 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anastrozole · Tamoxifen